PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders

Int J Mol Sci. 2018 Mar 20;19(3):913. doi: 10.3390/ijms19030913.

Abstract

Research in recent years on peroxisome proliferator-activated receptor (PPAR)β/δ indicates that it plays a key role in the maintenance of energy homeostasis, both at the cellular level and within the organism as a whole. PPARβ/δ activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease. This review highlights research findings on the PPARβ/δ regulation of energy metabolism and the development of diseases related to altered cellular and body metabolism. It also describes the potential of the pharmacological activation of PPARβ/δ as a treatment for human metabolic disorders.

Keywords: PPARβ/δ; dyslipidaemia; non-alcoholic fatty liver disease; obesity; type 2 diabetes mellitus.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / genetics*
  • Metabolic Diseases / metabolism
  • Molecular Targeted Therapy / methods
  • PPAR delta / agonists*
  • PPAR delta / genetics
  • PPAR delta / metabolism
  • PPAR-beta / agonists*
  • PPAR-beta / genetics
  • PPAR-beta / metabolism

Substances

  • PPAR delta
  • PPAR-beta